Advertisement

A comparison of EUS features between CD-117 positive GI stromal tumors and CD-117 negative GI spindle cell tumors

  • Gordon C. Hunt
    Affiliations
    Department of Medicine, Oregon Health and Science University, Portland VA Medical Center, Portland, Oregon USA

    Department of Pathology, Oregon Health and Science University, Portland VA Medical Center, Portland, Oregon USA
    Search for articles by this author
  • Anne E. Rader
    Affiliations
    Department of Medicine, Oregon Health and Science University, Portland VA Medical Center, Portland, Oregon USA

    Department of Pathology, Oregon Health and Science University, Portland VA Medical Center, Portland, Oregon USA
    Search for articles by this author
  • Douglas O. Faigel
    Correspondence
    Reprint requests: Douglas O. Faigel, MD, Portland Veterans Affairs Medical Center (P3GI), Portland, OR 97201.
    Affiliations
    Department of Medicine, Oregon Health and Science University, Portland VA Medical Center, Portland, Oregon USA

    Department of Pathology, Oregon Health and Science University, Portland VA Medical Center, Portland, Oregon USA
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.
      Background: GI stromal tumors are spindle cell tumors that stain positive for immunohistochemical CD-117 (c-kit). Prognostic factors for malignancy include size (≥4 cm), mitotic index (5 mitotic figures/50 high-powered fields), and ulcerated, cystic, or necrotic areas within the tumor. The purpose of this study was to compare these features in c-kit positive vs. c-kit negative tumors.
      Methods: All patients referred for EUS of submucosal lesions were identified, and histopathology, including immunohistochemical staining, was reviewed to determine all diagnoses of GI stromal tumors. Size, echo pattern, and presence of cystic spaces and ulceration were recorded as diagnosed by EUS. Histopathologic diagnoses were made by FNA or endoscopic submucosal-mucosal resection. If surgical resection followed, the surgical diagnosis, staining pattern, mitotic index, and presence of ulceration, necrosis, and nuclear atypia were recorded.
      Results: Forty patients (21 men, 19 women; 38 white, 2 African American; mean age 58±2.6 years) had 46 EUS procedures performed for evaluation of spindle cell tumors. Seventeen stained positive for c-kit (mean age, 59±3.6 years; range 19 to 80 years) and 12 negative (mean age, 57±3.8 years; range 31 to 76 years); 11 were not stained for c-kit (excluded from analysis). On EUS, 7 were ulcerated, 3 cystic, and 6 were larger than 4 cm. This group of findings was observed in 12 patients, 11 of whom had c-kit positive tumors (11/17 vs. 1/12; p=0.006). Tumors positive for c-kit were larger (42.4±5.5 mm vs. 19.0±5.9 mm; p=0.005). There were 13 c-kit positive tumors in the stomach, 2 in the duodenum, and 1 each in the esophagus and at the gastroesophageal junction. Of the 12 c-kit negative tumors, 8 were located in the esophagus and 1 at the gastroesophageal junction (9/12 vs. 2/17; p<0.01). Surgical resection was performed on 13 patients, 12 of whom had c-kit positive tumors, and 3 of these 12 tumors had greater than 5 mitoses per 50 high-powered field.
      Conclusions: If a GI stromal tumor is suspected, EUS-FNA with immunohistochemical staining should be performed for CD-117 (c-kit). C-kit tumors are more likely to have malignant features and should be resected or subjected to close clinical follow-up.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gastrointestinal Endoscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Miettinen M
        • Lasota J
        Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.
        Virchows Arch. 2001; 438: 1-12
        • Mazur MT
        • Clark HB
        Gastric stromal tumors. Reappraisal of histogenesis.
        Am J Surg Pathol. 1983; 7: 507-519
        • Miettinen M
        • Sarlomo-Rikala J
        • Lasota J
        Gastrointestinal stromal tumors: new findings on their biology. A review.
        Hum Pathol. 1999; 23: 1209-1220
        • Ueyama T
        • Guo KJ
        • Hashimoto H
        • Daimaru Y
        • Enjoji M
        A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors.
        Cancer. 1992; 69: 947-955
        • Hirota S
        • Isozaki K
        • Moriyama Y
        • Hashimoto K
        • Nishida T
        • Ishiguro S
        • et al.
        Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
        Science. 1998; 279: 577-580
        • Kindblom LG
        • Remotti HE
        • Aldenborg F
        • Meis-Kindblom JM
        Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.
        Am J Pathol. 1998; 152: 1259-1269
        • Miettinen M
        • Monihan JM
        • Sarlomo-Rikala M
        • Kovatich AJ
        • Carr NJ
        • Emory TS
        • et al.
        Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases.
        Am J Surg Pathol. 1999; 23: 1109-1118
        • Rader AE
        • Avery A
        • Wait CL
        • McGreevey LS
        • Faigel DO
        • Heinrich MC
        Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis of c-kit.
        Cancer. 2001; 93: 269-275
        • Berman J
        • O'Leary TJ
        Gastrointestinal stromal tumor workshop.
        Human Pathol. 2001; 32: 578-582
        • Robinson TL
        • Sircar K
        • Hewlett GR
        • Chorneyko K
        • Riddell RH
        • Huizing JD
        Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal.
        Am J Pathol. 2000; 156: 1157-1163
        • Li SQ
        • O'Leary TJ
        • Buchner SB
        • Przygodzki RM
        • Sobin LH
        • Erozan YS
        • et al.
        Fine needle aspiration of gastrointestinal stromal tumors.
        Acta Cytol. 2001; 45: 9-17
        • Ando N
        • Goto H
        • Niwa Y
        • Hirooka Y
        • Ohmiya N
        • Nagasaka T
        • et al.
        The diagnosis of GI stromal tumors with EUS-guided fine needle aspiration with immunohistochemical analysis.
        Gastrointest Endosc. 2002; 55: 37-43
        • Waxman I
        • Saitoh Y
        • Raju GS
        • Watari J
        • Yokota K
        • Reeves AL
        • et al.
        High-frequency probe EUS-assisted endoscopic mucosal resection: a therapeutic strategy for submucosal tumors of the GI tract.
        Gastrointest Endosc. 2002; 55: 44-49
        • Chak A
        • Canto MI
        • Rösch T
        • Dittler HJ
        • Hawes RH
        • Tio TL
        • et al.
        Endosonographic differentiation of benign and malignant stromal cell tumors.
        Gastrointest Endosc. 1997; 45: 468-473
        • Zhang Q-L
        • Nian WD
        Endoscopic ultrasonography diagnosis in submucosal tumor of stomach [review].
        Endoscopy. 1998; 30: A69-A71
        • Nesje LB
        • Laerum OD
        • Svanes K
        • Odegaard S
        Subepithelial masses of the gastrointestinal tract evaluated by endoscopic ultrasonography.
        Eur J Ultrasound. 2002; 15: 45-54
        • Miettinen M
        • Sarlomo-Rikala M
        • Sobin LH
        • Lasota J
        Gastrointestinal stromal tumors and leiomyosarcomas in the colon. A clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases.
        Am J Surg Pathol. 2000; 24: 1339-1352
        • Graadt van Roggen JF
        • van Velthuysen ML
        • Hogendoorn PC
        The histopathological differential diagnosis of gastrointestinal stromal tumours.
        J Clin Pathol. 2001; 54: 96-103
        • Miettinen M
        • Sarlomo-Rikala M
        • Sobin LH
        • Lasota J
        Esophageal stromal tumors. A clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas.
        Am J Surg Pathol. 2000; 24: 211-222
        • Taniguchi M
        • Nishida T
        • Hirota S
        • Isozaki K
        • Ito T
        • Nomura T
        • et al.
        Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.
        Cancer Res. 1999; 59: 4297-4300
        • Lasota J
        • Jasinski M
        • Sarlomo-Rikala M
        • Miettinen M
        Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas.
        Am J Pathol. 1999; 154: 53-60
        • Matsui M
        • Goto H
        • Niwa Y
        • Arisawa T
        • Hirooka Y
        • Hayakawa T
        Preliminary results of fine needle aspiration biopsy histology in upper gastrointestinal submucosal tumors.
        Endoscopy. 1998; 30: 750-755
        • Kim CJ
        • Day S
        • Yeh KA
        Gastrointestinal stromal tumors: analysis of clinical and pathologic factors.
        Am Surg. 2001; 67: 135-137
        • Hizawa K
        • Matsumoto T
        • Kouzuki T
        • Suekane H
        • Esaki M
        • Fujishima M
        Cystic submucosal tumors in the gastrointestinal tract: Endosonographic findings and endoscopic removal.
        Endoscopy. 2000; 32: 712-714
        • Tandon M
        • Topazian M
        Metastatic carcinoma simulating stromal tumor.
        Gastrointest Endosc. 2002; 55: 717
        • Tuveson DA
        • Willis NA
        • Jacks T
        • Griffin JD
        • Singer S
        • Fletcher CD
        • et al.
        STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.
        Oncogene. 2001; 20: 5054-5058
        • Demetri GD
        • von Mehren M
        • Blanke CD
        • Van den Abbeele AD
        • Eisenberg B
        • Roberts PJ
        • et al.
        Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
        N Engl J Med. 2002; 347: 472-480